vspВопросы современной педиатрииCurrent Pediatrics1682-55271682-5535Издательство «ПедиатрЪ»10.15690/vsp.v11i6.508vsp-416Research ArticleКЛИНИЧЕСКИЕ НАБЛЮДЕНИЯCLINICAL OBSERVATIONSАНТИ-CD20 МОНОКЛОНАЛЬНЫЕ АНТИТЕЛА В ТЕРАПИИ ГЕМОЛИТИЧЕСКОЙ АНЕМИИ У ДЕВОЧКИ-ПОДРОСТКА С СИСТЕМНОЙ КРАСНОЙ ВОЛЧАНКОЙANTI-CD20 MONOCLONAL ANTIBODIES IN TREATMENT OF HAEMOLYTIC ANEMIA IN A TEENAGE GIRL WITH SYSTEMIC LUPUS ERYTHEMATOSUSДенисоваР. В.DenisovaR. V.denisovarv@yandex.ruАлексееваЕ. И.AlexeevaE. I.alekatya@ya.ruНаучный центр здоровья детей РАМН, МоскваРоссияScientific Centre of Children Health, RAMS, MoscowRussian FederationНаучный центр здоровья детей РАМН, Москва; Первый московский государственный медицинский университет им. И.М. СеченоваРоссияScientific Centre of Children Health, RAMS, Moscow; I.M. Sechenov First Moscow State Medical UniversityRussian Federation201219112012116Вопросы современной педиатрии147152Copyright © Денисова Р.В., Алексеева Е.И., 20122012Денисова Р.В., Алексеева Е.И.Denisova R.V., Alexeeva E.I.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://vsp.spr-journal.ru/jour/article/view/416

Гемолитическая анемия встречается в 10% случаев системной красной волчанки у детей с гематологическими изменениями. Для лечения данного состояния применяют высокие дозы глюкокортикоидов. Препаратами второй линии при рефрактерном течении заболевания являются азатиоприн, микофенолата мофетил, циклоспорин и циклофосфамид. Ритуксимаб — анти-CD20 моноклональное антитело — используют для лечения системной красной волчанки, рефрактерной к стандартной иммуносупрессивной терапии. В данной статье представлен случай успешной терапии гемолитической анемии у девочки-подростка с системной красной волчанкой. Назначение ритуксимаба позволило избежать повышения дозы глюкокортикоидов и назначения циклофосфамида, а также предотвратить развитие тяжелых нежелательных явлений от терапии высокими дозами этих препаратов. Однако для изучения продолжительности эффекта, безопасности терапии, подбора его оптимальной дозы необходимы данные многоцентровых рандомизированных контролируемых исследований.

системная красная волчанкаритуксимабгемолитическая анемияантифосфолипидный синдромsystemic lupus erythematosusrituximabhaemolytic anemiaantiphospholipid syndromeReferencesPetty R. E., Laxer R. M. Systemic lupus erythematosus. In: J. T. Cassidy, R. E. Petty, R. M. Laxer, C. B. Lindsley (eds.). Textbook of pediatric rheumatology. Philadelphia, PA: Elsevier Saunders. 2005. P. 342–391.Petty R. E., Laxer R. M. Systemic lupus erythematosus. In: J. T. Cassidy, R. E. Petty, R. M. Laxer, C. B. Lindsley (eds.). Textbook of pediatric rheumatology. Philadelphia, PA: Elsevier Saunders. 2005. P. 342–391.Tucker L. B., Menon S., Scharler J. G., Isenberg D. A. Adult and childhood-onset systemic lupus erythematosus: a comparison of onset, clinical features, serology and outcome. Br. J. Rheumatol. 1995; 34: 866–872.Tucker L. B., Menon S., Scharler J. G., Isenberg D. A. Adult and childhood-onset systemic lupus erythematosus: a comparison of onset, clinical features, serology and outcome. Br. J. Rheumatol. 1995; 34: 866–872.Carreno L., Lopez-Longo F. J., Monteagudo I. Rodriguez- Mahou M., Bascones M., Gonzalez C. M., Saint-Cyr C., Lapointe N. Immunological and clinical differences between juvenile and adult onset of systemic lupus erytematosus. Lupus. 1999; 8: 287–292.Carreno L., Lopez-Longo F. J., Monteagudo I. Rodriguez- Mahou M., Bascones M., Gonzalez C. M., Saint-Cyr C., Lapointe N. Immunological and clinical differences between juvenile and adult onset of systemic lupus erytematosus. Lupus. 1999; 8: 287–292.Costallat L. T., Coimbra A. M. Systemic lupus erythematosis; clinical and laboratory aspects related to age at disease onset. Clin. Exp. Rheumatol. 1994; 12: 603–607.Costallat L. T., Coimbra A. M. Systemic lupus erythematosis; clinical and laboratory aspects related to age at disease onset. Clin. Exp. Rheumatol. 1994; 12: 603–607.Cervera R., Kamashtha M. A., Font J., Sebastiani G. D., Gil A., Lavilla P., Domenech I., Aydintug A. O., Jedryka-Goral A., de Ramon E. Systemic lupus erythematosus: clinical and immunologic patterns of disease expression in a cohort of 1000 patients. Medicine. 1993; 72: 113–124.Cervera R., Kamashtha M. A., Font J., Sebastiani G. D., Gil A., Lavilla P., Domenech I., Aydintug A. O., Jedryka-Goral A., de Ramon E. Systemic lupus erythematosus: clinical and immunologic patterns of disease expression in a cohort of 1000 patients. Medicine. 1993; 72: 113–124.Pugh-Bernard A. E., Cambier J. C. B cell receptor signaling in human systemic lupus erythematosus. Curr. Opin. Rheumatol. 2006; 18: 451–455.Pugh-Bernard A. E., Cambier J. C. B cell receptor signaling in human systemic lupus erythematosus. Curr. Opin. Rheumatol. 2006; 18: 451–455.Mohan C., Datta S. K. Lupus: key pathogenic mechanisms and contributing factors. Clin. Immunol. Immunopathol. 1995; 77: 209–220.Mohan C., Datta S. K. Lupus: key pathogenic mechanisms and contributing factors. Clin. Immunol. Immunopathol. 1995; 77: 209–220.Prodeus A. P., Goerg S., Shen L. M., Pozdnyakova O. O., Chu L., Alicot E. M., Goodnow C. C., Carroll M. C. A critical role for complement in maintenance of self-tolerance. Immunity. 1998; 9: 721–731.Prodeus A. P., Goerg S., Shen L. M., Pozdnyakova O. O., Chu L., Alicot E. M., Goodnow C. C., Carroll M. C. A critical role for complement in maintenance of self-tolerance. Immunity. 1998; 9: 721–731.Yurasov S., Wardemann H., Hammersen J. Tsuiji M., Meffre E., Pascual V., Nussenzweig M.C. Defective B cell tolerance checkpoints in systemic lupus erythematosus. J. Exp. Med. 2005; 20: 703–711.Yurasov S., Wardemann H., Hammersen J. Tsuiji M., Meffre E., Pascual V., Nussenzweig M.C. Defective B cell tolerance checkpoints in systemic lupus erythematosus. J. Exp. Med. 2005; 20: 703–711.Shan D., Ledbetter J. A., Press O. W. Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells. Cancer Immunol. Immunother 2000; 48: 673–683.Shan D., Ledbetter J. A., Press O. W. Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells. Cancer Immunol. Immunother 2000; 48: 673–683.Flieger D., Renoth S., Beier I., Sauerbruch T., Schmidt-Wolf I. Mechanism of cytotoxicity induced by chimeric mouse human monoclonal antibody IDEC–C2B8 in CD20-expressing lymphoma cell lines. Cell Immunol. 2000; 204: 55–63.Flieger D., Renoth S., Beier I., Sauerbruch T., Schmidt-Wolf I. Mechanism of cytotoxicity induced by chimeric mouse human monoclonal antibody IDEC–C2B8 in CD20-expressing lymphoma cell lines. Cell Immunol. 2000; 204: 55–63.Alas S., Emmanouilides C., Bonavida B. Inhibition of interleukin 10 by rituximab results in down-regulation of bcl-2 and sensitization of Bcell non-Hodgkin’s lymphoma to apoptosis. Clin. Cancer Res. 2001; 7: 709–723.Alas S., Emmanouilides C., Bonavida B. Inhibition of interleukin 10 by rituximab results in down-regulation of bcl-2 and sensitization of Bcell non-Hodgkin’s lymphoma to apoptosis. Clin. Cancer Res. 2001; 7: 709–723.Anolik J. H., Campbell D., Felgar R. E. Young F., Sanz I., Rosenblatt J., Looney R.J. The relationship of Fc_RIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus. Arthritis Rheum. 2003; 48: 455–459.Anolik J. H., Campbell D., Felgar R. E. Young F., Sanz I., Rosenblatt J., Looney R.J. The relationship of Fc_RIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus. Arthritis Rheum. 2003; 48: 455–459.Boye J., Elter T., Engert A. An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab. Ann. Oncol. 2003; 14: 520–535.Boye J., Elter T., Engert A. An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab. Ann. Oncol. 2003; 14: 520–535.El-Hallak M., Binstadt B. A., Leichtner A. M. Bennett C.M., Neufeld E.J., Fuhlbrigge R.C., Zurakowski D., Sundel R.P. Clinical effects and safety of rituximab for treatment of refractory pediatric autoimmune diseases. J. Pediatr. 2007; 150: 376–382.El-Hallak M., Binstadt B. A., Leichtner A. M. Bennett C.M., Neufeld E.J., Fuhlbrigge R.C., Zurakowski D., Sundel R.P. Clinical effects and safety of rituximab for treatment of refractory pediatric autoimmune diseases. J. Pediatr. 2007; 150: 376–382.Giulino L. B., Brussel J. B., Neufeld E. J. Pediatric and Platelet Immmunology Committees of the TMH Clinical Trial Network. Treatment with rituximab in benign and malignant hematologic disorders in children. J. Pediatr. 2007; 150: 338–344.Giulino L. B., Brussel J. B., Neufeld E. J. Pediatric and Platelet Immmunology Committees of the TMH Clinical Trial Network. Treatment with rituximab in benign and malignant hematologic disorders in children. J. Pediatr. 2007; 150: 338–344.Bensler S. M., Silverman E. D. Systemic lupus erythematosus. Pediatr. Clin. North Am. 2005; 5: 443–467. 18. Saito K., Nawata M., Nakayamada S., Tokunaga M., Tsukada J., Tanaka Y. Successful treatment with anti-CD20 monoclonal antibody (rituximab) of life threatening refractory systemic lupus erythematosus with renal and central nervous system involvement. Lupus. 2003; 12: 798–800.Bensler S. M., Silverman E. D. Systemic lupus erythematosus. Pediatr. Clin. North Am. 2005; 5: 443–467. 18. Saito K., Nawata M., Nakayamada S., Tokunaga M., Tsukada J., Tanaka Y. Successful treatment with anti-CD20 monoclonal antibody (rituximab) of life threatening refractory systemic lupus erythematosus with renal and central nervous system involvement. Lupus. 2003; 12: 798–800.Kotani T., Takeuchi T., Kawasaki Y. Hirano S., Tabushi Y., Kagitani M., Makino S., Hanafusa T. Successful treatment of cold agglutin disease with anti CD20 antibody (rituximab) in patient with systemic lupus erythematosus. Lupus. 2006; 15: 683–685.Kotani T., Takeuchi T., Kawasaki Y. Hirano S., Tabushi Y., Kagitani M., Makino S., Hanafusa T. Successful treatment of cold agglutin disease with anti CD20 antibody (rituximab) in patient with systemic lupus erythematosus. Lupus. 2006; 15: 683–685.Gomard-Mennesson E., Ruivard M., Koenig M., Woods A., Magy N., Ninet J., Rousset H., Salles G., Broussolle C., Sуve P. Treatment of islolated severe immune hemolytic anemia associated with systemic lupus erythematosus: 26 cases. Lupus. 2006; 15: 223–231.Gomard-Mennesson E., Ruivard M., Koenig M., Woods A., Magy N., Ninet J., Rousset H., Salles G., Broussolle C., Sуve P. Treatment of islolated severe immune hemolytic anemia associated with systemic lupus erythematosus: 26 cases. Lupus. 2006; 15: 223–231.Perrotta S., Locatelli F., La Manna A., Cennamo L., De Stefano P., Nobili B. Anti-CD20 monoclonal antibody (rituximab) for lifethreatening autoimmune haemolytic anaemia in a patient with systemic lupus erythematosus. Br. J. Haematol. 2002; 116: 465–467.Perrotta S., Locatelli F., La Manna A., Cennamo L., De Stefano P., Nobili B. Anti-CD20 monoclonal antibody (rituximab) for lifethreatening autoimmune haemolytic anaemia in a patient with systemic lupus erythematosus. Br. J. Haematol. 2002; 116: 465–467.Zecca M., Nobili B., Ramenghi U., Perrotta S., Amendola G., Rosito P., Jankovic M., Pierani P., De Stefano P., Bonora M. R., Locatelli F. Rituximab for the treatment of refractory autoimmune hemolytic anemia in children. Blood. 2003; 101: 3857–3861.Zecca M., Nobili B., Ramenghi U., Perrotta S., Amendola G., Rosito P., Jankovic M., Pierani P., De Stefano P., Bonora M. R., Locatelli F. Rituximab for the treatment of refractory autoimmune hemolytic anemia in children. Blood. 2003; 101: 3857–3861.Willems M., Haddad E., Niaudet P., Kone-Paut I., Bensman A., Cochat P., Deschenes G., Fakhouri F., Leblanc T., Llanas B., Loirat C., Pillet P., Ranchin B., Salomon R., Ulinski T., Bader-Meunier B. French Pediatric-Onset SLE Study Group. Rituximab therapy for childhood-onset systemic lupus erythematosus. J. Pediatr. 2006; 148: 623–627.Willems M., Haddad E., Niaudet P., Kone-Paut I., Bensman A., Cochat P., Deschenes G., Fakhouri F., Leblanc T., Llanas B., Loirat C., Pillet P., Ranchin B., Salomon R., Ulinski T., Bader-Meunier B. French Pediatric-Onset SLE Study Group. Rituximab therapy for childhood-onset systemic lupus erythematosus. J. Pediatr. 2006; 148: 623–627.Abdwani R., Mani R. Anti-CD20 monoclonal antibody in acute life threatening haemolytic anaemia complicating childhood onset SLE. Lupus. 2009; 18: 460–464.Abdwani R., Mani R. Anti-CD20 monoclonal antibody in acute life threatening haemolytic anaemia complicating childhood onset SLE. Lupus. 2009; 18: 460–464.Laxer R. M. Pharmacology and drug therapy. In: J. T. Cassidy, R. E. Petty, R. M. Laxer, C. B. Lindsley (eds.). Textbook of pediatric rheumatology. Philadelphia, PA: Elsevier Saunders. 2005. P. 76–141.Laxer R. M. Pharmacology and drug therapy. In: J. T. Cassidy, R. E. Petty, R. M. Laxer, C. B. Lindsley (eds.). Textbook of pediatric rheumatology. Philadelphia, PA: Elsevier Saunders. 2005. P. 76–141.Byrd J. C., Murphy T., Howard R. S., Lucas M. S., Goodrich A., Park K., Pearson M., Waselenko J. K., Ling G., Grever M. R., Grillo- Lopez A. J., Rosenberg J., Kunkel L., Flinn I. W. Rituximab using a thriceweekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J. Clin. Oncol. 2001; 19: 2153–2164.Byrd J. C., Murphy T., Howard R. S., Lucas M. S., Goodrich A., Park K., Pearson M., Waselenko J. K., Ling G., Grever M. R., Grillo- Lopez A. J., Rosenberg J., Kunkel L., Flinn I. W. Rituximab using a thriceweekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J. Clin. Oncol. 2001; 19: 2153–2164.Package insert: Rituxan (rituximab). San Diego, CA: IDEC Pharmaceuticals Corp. 2003.Package insert: Rituxan (rituximab). San Diego, CA: IDEC Pharmaceuticals Corp. 2003.Алексеева Е. И., Валиева С. И., Бзарова Т. М. Семикина Е. Л., Исаева К. Б., Лисицын А. О., Денисова Р. В., Гудкова Е. Ю. Эффек- тивность и безопасность повторных курсов лечения ритуксима- бом тяжелого рефрактерного ювенильного артрита. Вопр. совр. педиатрии. 2009; 8 (5): 19–30.Алексеева Е. И., Валиева С. И., Бзарова Т. М. Семикина Е. Л., Исаева К. Б., Лисицын А. О., Денисова Р. В., Гудкова Е. Ю. Эффек- тивность и безопасность повторных курсов лечения ритуксима- бом тяжелого рефрактерного ювенильного артрита. Вопр. совр. педиатрии. 2009; 8 (5): 19–30.Alexeeva E.I., Valieva S.I., Bzarova T.M., Semikina E.L., Isaeva K.B., Lisitsyn A.O., Denisova R.V., Chistyakova E.G. Efficacy and safety of repeat courses of rituximab treatment in patients with severe refractory juvenile idiopathic arthritis. Clin. Rheumatol. 2011; 30 (9): 1163–1172.Alexeeva E.I., Valieva S.I., Bzarova T.M., Semikina E.L., Isaeva K.B., Lisitsyn A.O., Denisova R.V., Chistyakova E.G. Efficacy and safety of repeat courses of rituximab treatment in patients with severe refractory juvenile idiopathic arthritis. Clin. Rheumatol. 2011; 30 (9): 1163–1172.MacDermott E. J., Lehman T. J. Prospective, open-label trial of rituximab in childhood systemic lupus erythematosus. Curr. Rheumatol. Rep. 2006; 8: 439–441.MacDermott E. J., Lehman T. J. Prospective, open-label trial of rituximab in childhood systemic lupus erythematosus. Curr. Rheumatol. Rep. 2006; 8: 439–441.Marks S. D., Patey S., Borgan P. A., Hasson N., Pilkington C., Woo P., Tullus K. B lymphocyte depletion therapy in children with refractory systemic lupus erythmatosus. Arthritis Rheum. 2005; 52: 3168–3173.Marks S. D., Patey S., Borgan P. A., Hasson N., Pilkington C., Woo P., Tullus K. B lymphocyte depletion therapy in children with refractory systemic lupus erythmatosus. Arthritis Rheum. 2005; 52: 3168–3173.Poldolskaya A., Stdermann M., Pilikington C., Mark S. D., Tullus K. Bcell depletion therapy for 19 patients with refractory lupus erythematosus. Arch. Dis. Child. 2008; 93: 401–406.Poldolskaya A., Stdermann M., Pilikington C., Mark S. D., Tullus K. Bcell depletion therapy for 19 patients with refractory lupus erythematosus. Arch. Dis. Child. 2008; 93: 401–406.Nwobi O., Abitbol C. L., Chandar J., Seeherunvong W., Zilleruelo G. Rituximab therapy for juvenile-onset systemic lupus erythematosus. Pediatr. Nephrol. 2008; 23: 413–419 (abstract).Nwobi O., Abitbol C. L., Chandar J., Seeherunvong W., Zilleruelo G. Rituximab therapy for juvenile-onset systemic lupus erythematosus. Pediatr. Nephrol. 2008; 23: 413–419 (abstract).

The authors declare that there are no conflicts of interest present.